Abstract
Combination chemotherapy of mFOLFOX6 (5-fluorouracil, leucovorin, and oxaliplatin) plus panitumumab, a fully human monoclonal antibody against epidermal growth factor receptor (EGFR), is one of the standard treatments for metastatic colorectal cancer (mCRC) without KRAS mutation. A few reports suggested no need of dose adjustment of cetuximab, a similar chimeric anti-EGFR antibody, in patients with renal impairment. However, panitumumab combined with cytotoxic drugs for hemodialysis patients has not been reported. We herein report a case of a hemodialysis mCRC patient successfully treated with mFOLFOX6 and panitumumab combination therapy.
MeSH terms
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Cecal Neoplasms / drug therapy*
-
Cecum / pathology
-
ErbB Receptors / antagonists & inhibitors*
-
ErbB Receptors / genetics
-
Fluorouracil / administration & dosage
-
Fluorouracil / therapeutic use
-
Humans
-
Leucovorin / administration & dosage
-
Leucovorin / therapeutic use
-
Male
-
Middle Aged
-
Mutation
-
Organoplatinum Compounds / administration & dosage
-
Organoplatinum Compounds / therapeutic use
-
Panitumumab
-
Renal Dialysis
Substances
-
Antibodies, Monoclonal
-
Organoplatinum Compounds
-
Panitumumab
-
EGFR protein, human
-
ErbB Receptors
-
Leucovorin
-
Fluorouracil